Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are key drugs in the treatment of non‐small cell lung cancer (NSCLC) patients with EGFR mutations; however, first‐generation EGFR‐TKIs, such as gefitinib and erlotinib, are not effective in patients with uncommon EGFR mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Tomoki, Kawakado, Keita, Makimoto, Go, Nakanishi, Masamoto, Kuyama, Shoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169299/
https://www.ncbi.nlm.nih.gov/pubmed/33942527
http://dx.doi.org/10.1111/1759-7714.13941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169299/
https://www.ncbi.nlm.nih.gov/pubmed/33942527
http://dx.doi.org/10.1111/1759-7714.13941

Ejemplares similares